Rare Tapeworm Infection due to Dipylidium caninum: Case Report
Dr.Catherine A. Hogan, and Dr. Hayden Schwenk, at Stanford University School of Medicine, Stanford, CA have reported a rare case of Dipylidium caninum Infection. The case has appeared in the New England Journal of Medicine.
Treatment is with a single oral dose of praziquantel 5 to 10 mg/kg. Alternatively, a single 2-g dose of niclosamide (unavailable in the US) is given as 4 tablets (500 mg each) that are chewed one at a time and swallowed. For children, the dose is 50 mg/kg (maximum 2 g) once.
According to history, a 2-year-old girl presented to the pediatric infectious disease clinic with visible worms in the stool and mild perianal pruritus. Tests for ova and parasites in the stool were initially negative. The patient’s mother reported that several pet cats in the household were passing similar worms and had been treated empirically by a veterinarian. The patient’s mother brought a freshly passed proglottid in a sterile container filled with saline for further assessment.
Microscopic examination of the proglottid confirmed the presence of egg packets that were diagnostic of the tapeworm Dipylidium caninum on both wet mount (Panel A) and iodine staining (Panel B). D. caninum infection typically occurs in dogs and cats but may occur in humans after ingestion of an adult flea harboring an infective cysticercoid, particularly in children living in close proximity to infected dogs or cats. The patient was treated with a single dose of praziquantel. At follow-up 3 weeks later, the perianal pruritus had resolved, and there was no recurrence of proglottids in the stool.
For further reference log on to DOI: 10.1056/NEJMicm1813985
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd